- Home
- BMEA vs AEC Comparison
BMEA vs AEC Comparison
Compare BMEA & AEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- AEC
- Stock Information
- Founded
- BMEA 2017
- AEC 1989
- Country
- BMEA United States
- AEC Canada
- Employees
- BMEA N/A
- AEC N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- AEC Real Estate Investment Trusts
- Sector
- BMEA Health Care
- AEC Real Estate
- Exchange
- BMEA Nasdaq
- AEC Nasdaq
- Market Cap
- BMEA 125.0M
- AEC 110.9M
- IPO Year
- BMEA 2021
- AEC N/A
- Fundamental
- Price
- BMEA $2.15
- AEC $9.62
- Analyst Decision
- BMEA Strong Buy
- AEC
- Analyst Count
- BMEA 8
- AEC 0
- Target Price
- BMEA $10.63
- AEC N/A
- AVG Volume (30 Days)
- BMEA 658.3K
- AEC 176.3K
- Earning Date
- BMEA 10-28-2025
- AEC 01-01-0001
- Dividend Yield
- BMEA N/A
- AEC N/A
- EPS Growth
- BMEA N/A
- AEC N/A
- EPS
- BMEA N/A
- AEC N/A
- Revenue
- BMEA N/A
- AEC N/A
- Revenue This Year
- BMEA N/A
- AEC N/A
- Revenue Next Year
- BMEA N/A
- AEC N/A
- P/E Ratio
- BMEA N/A
- AEC N/A
- Revenue Growth
- BMEA N/A
- AEC N/A
- 52 Week Low
- BMEA $1.29
- AEC $6.00
- 52 Week High
- BMEA $13.07
- AEC $10.98
- Technical
- Relative Strength Index (RSI)
- BMEA 61.18
- AEC N/A
- Support Level
- BMEA $1.98
- AEC N/A
- Resistance Level
- BMEA $2.18
- AEC N/A
- Average True Range (ATR)
- BMEA 0.12
- AEC 0.00
- MACD
- BMEA 0.01
- AEC 0.00
- Stochastic Oscillator
- BMEA 75.76
- AEC 0.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.